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1. Introduction 
In cardiac surgery, hyperglycemia is a common occurrence in patients with and without 
diabetes (1,2). For many years, stress-induced hyperglycemia was considered an adaptive and 
beneficial response of the organism. However, both human and animal studies suggest that it 
is not a benign condition and, in contrast, it is associated with a high risk of morbidity and 
mortality. Stress hyperglycemia is defined as an elevation of plasma glucose levels (above 126 
mg/dl in fasting condition or 200 mg/dl at any time) in critically ill or hospitalized patients, 
with or without history of diabetes (3). More specifically, elevated values of blood glucose in 
presence of normal levels of glycosylated hemoglobin (HbA1c), regardless of diabetes status, 
may be considered a stress response; this kind of hyperglycemia is developed during any 
physiological reaction to a situation of high metabolic demand or injury, in which diverse 
mechanisms become active for maintaining homeostasis, for example: major burns, severe 
trauma, hemorrhage, septicemia, and major surgery, in which it is very common for blood 
sugar to reach levels up to 370 mg/dl (4). It was the French physiologist Claude Bernard who 
first described this phenomenon in dogs subjected to hemorrhagic shock in 1885 (5); since 
then, this finding has been extensively studied, especially in recent decades because of it´s 
impact on outcomes of critically ill patients. 
Hyperglycemia is a well recognized condition that increases the overall hospital morbidity 
and mortality of any patient admitted for any reason. In addition, it also increases the rate of 
complications in diabetic and non-diabetic patients undergoing major surgeries; besides this 
condition is associated with a longer hospital-stay and higher costs (1). Considering the 
strong association between hyperglycemia and general morbidity and mortality in surgery, 
there has been great interest for developing protocols to control blood-glucose levels during 
the perioperative period in order to prevent hyperglycemia, to achieve euglycemia and to 
reduce episodes of hypoglycemia, aiming the improvement of patient outcomes. In 
particular, the glycemic control in cardiac surgery has become a very important matter in 
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the full standard care as a mean of reducing infections and further complications, and in 
consequence, the patient’s improvement. 
This chapter reviews the mechanisms of stress hyperglycemia, the evidence of the 
association between hyperglycemia and adverse outcomes in surgical patients particularly 
in cardiac surgery. Besides, it offers a general overview about discordant reports found in 
the literature on the strict glycemic control during the peri-operative period of a cardiac 
surgery. In addition to, it also recommends common approaches to control the glycemia in 
surgical intensive care unit (ICU) and post-surgical cardiovascular patients based on the 
best performed randomized controlled trials. 
2. Mechanisms of stress hyperglycemia 
Stress Hyperglycemia, also called stress-induced diabetes, diabetes (6), is a multifact 
metabolic disorder that is characterized by the presence of hyperglycemia with 
hyperinsulinemia, peripheral resistance to insulin and an over-production of glucose by 
different mechanisms that result in incremented glycogenolysis and increased 
gluconeogenesis. Figure 1 shows how endogenous and exogenous predisposing factors may 
trigger the development of stress hyperglycemia, particularly during a cardiac surgery. The 
most important trigger is the surgical stress itself that conduces to a catabolic state that 
results in high levels of blood-glucose; the appearance of stress-hormones and a diminished 
peripheral response to insulin, cause hyperglycemia, and raises even more previous 
glycemia breeding an abnormal immune response (3, 6-9.). Stress hyperglycemia is caused 
mainly by the effects of counter-regulatory hormones (catecholamines, growth hormone, 
and cortisol) and by depletion of the functional reserve of the beta-cells in the Langerhans 
islets of the pancreas (7). During perioperative period of major surgeries, the counter-
regulatory hormones and the inflammatory response induced by surgical stress are the most 
important triggers of hyperglycemia (10). The degree of insulin resistance has been related 
to the magnitude and endurance of surgical stress. In addition, it has been reported that in 
the perioperative period, increased glucose reabsorption or decreased renal glucose 
clearance may enhance this phenomena that contribute to hyperglycemia (11).  
Predisposing factors 
Although stress hyperglycemia is mainly caused by six events: severe trauma, bleeding, 
hypothermia, septicemia, severe burns and great-magnitude surgeries, there are several 
factors that may contribute to this alteration, which could and should be explored in the 
preoperative examinations (Table 1). All of these predisposing factors can be divided in 
endogenous and exogenous factors. 
a. Endogenous factors 
The first and most important predisposing factor for developing stress hyperglycemia is to 
be previously diagnosed with Diabetes Mellitus; in this case glucose blood-levels after 
cardiac surgery may reach even 20 mmol/l (370mg/dl) or more, compared with non-
diabetic patients which might reach 15 mmol/l (270 mg/ml) (12-14). With a previous 
diagnosis of diabetes, it is not just more likely to develop stress hyperglycemia, but this one 
is more severe. 
Other endogenous factor is acute pain which inhibits the suppression of endogenous 
glucose by insulin; in addition, it releases diverse acute-stress hormones that contribute 
hyperglycemia, such as cortisol, glucagon, growth hormone, etc. (15). It has been impossible 
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Fig. 1. It is showed how endogenous and exogenous predisposing factors may trigger the 
developing of stress hyperglycemia, adding cardiac surgery’s aggression. Physiological-
stress triggers a catabolic state that results in stress hyperglycemia; the appearance of stress-
released hormones and a diminished peripheral response to insulin augment glycemia, and 
condition the release of proteins and free fatty acids that in addition to hyperglycemia entail 
an abnormal immune response. 
to quantify the real affection caused by pain in the glucose-metabolism, but the tendency of 
an aggressive-pain management might be helpful for decreasing the peripheral resistance to 
insulin (16). 
Elderly patients represent an important group that undergoes cardiac surgeries; it is well 
known that insulin secretion is diminished in this group of age. This is reinforced by 
different studies; the comparison between patients over 60 years versus younger people 
shows incidence-reduction of hyperglycemia up to 38% in young adults (17). So, elderliness 
is a very important factor for elevated blood glucose levels (18).  
b. Exogenous factors 
Hypothermia, especially present in coronary bypass surgery due to cardioplegic solutions, 
provokes hyperglycemia by inhibiting the negative-feedback of the insulin response (19). 
Also, desaturation and arterial hypoxemia, increase a sympathetic autonomous response 
that favors glucagon release by an alpha-receptor action (20). 
Many drugs commonly used with inpatient care might modify glucose metabolism. Some of 
them are well known as ‘diabetogenic’ medications such as glucocorticoids and opiates; 
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Action Factor 
Insulin deficiency (relative or 
absolute)/Insulin resistance 
Diabetes mellitus 
Higher counterregulatory hormone levels 
Acute Pain 
Elevated Acute Physiology and Chronic 
Health Evaluation (APACHE) score 
Insulin Peripheral resistance 
Catecholamine-Infusion 
Glucocorticoid treatment 
Overweight 
Septicemia/Sepsis/Septic Shock 
Uremia 
Bed rest 
Fasting 
Insulin impaired secretion 
Elderly 
Hypothermia 
Hypoxemia 
Modified from ref. 29: McCowen KC, Malhotra A, Bistrian BR. Stress-induced hyperglycemia. Crit Care 
Clin 2001; 17: 107-24. 
Table 1. Predisposing factors for developing stress hyperglycemia 
others are used for treating hypertension such as calcium channel blockers, clortalidone, and 
prazosin. Every synthetic catecholamine or catecholamine-agonist or blocker (such as 
epinephrine, norepinephrine, salbutamol, metoprolol, propanolol) and tricyclic anti-
depressants, might elevate glucose levels. Particularly, catecholamine-infusion during 
cardiac surgery contributes greatly to this metabolic state during surgery, as well as in the 
early postoperative period; it might also overlap and/or worsen stress response. Even 
alcohol and salicylates raise glycemia. All volatile anesthetic agents, including halothane, 
enflurane, and isoflurane, inhibit the insulin response to glucose in a dose dependent 
manner in vitro (21). The hyperglycemic response during inhaled anesthesia with isoflurane 
is a consequence of both impaired glucose clearance and increased glucose production 
(22,23). 
Other factor that contributes to augment glycemia is bed resting. This condition reduces the 
sensitivity of the skeletal muscle to insulin, and in consequence increases fasting plasma 
insulin concentration as well as oral glucose challenge; insulin clamp studies showed no 
insulin secretion deficiency during repose. This response is mainly because of proteolysis 
that reduces total muscle mass and decreases the total number of transporters (24). 
Other exogenous factor is the preoperative fasting. Fasting is a routinely action taken before 
undergoing a programmed cardiac surgery; fasting before surgery diminishes the glycogen 
reserve, induces protein breakdown (that releases alanine) and might disrupt insulin action 
and the stress responsiveness (25). 
An underappreciated cause of hyperglycemia in critically ill patients is the provision of 
dextrose in excessive of amounts that can be easily oxidized or stored. In addition to 
hyperglycemia, other complications may result from the administration of dextrose over the 
rate of 4 mg/kg/min, inducing lipogenesis and increased carbon dioxide production (26). 
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The role of the glucose transporters 
Stress-induced diabetes seems to be supported mainly by peripheral resistance to insulin, 
i.e. the inability of skeletal muscles and adipocytes to uptake glucose. This condition 
appears because of the affection of the glucose transporter type 4, called GLUT4 which is 
dependent of insulin. This very important hexose-transporter is located in skeletal-muscle, 
cardiac muscle and adipocytes (27). This protein is member of a family of transmembranal 
proteins that are responsible for uptaking glucose in different cells which depend of insulin 
for their action. These transporters are responsible of plenty of physiological phenomena 
that maintain glucose homeostasis (28,29). The physiological stress inhibits -by different 
mechanisms- the insulin’s action on the GLUT4, mainly by impairing the phosphorylation of 
several molecules of the intracellular signaling pathway of insulin (30); the result is a 
decreased function of the transporter and therefore, a diminution of insulin-mediated 
glucose uptake. Additionally, the transporters GLUT1 (present in endothelial and non-
skeletal muscle cells) and GLUT3 (present in neurons) are affected –as well as GLUT4 -by 
diverse cytokines such as IL-1, IL-6 and C-Reactive Protein which are augmented in surgical 
stress (29, 31,32). 
Non-glucosydic substrates used during stress hyperglycemia 
The carbohydrate metabolism during periods of stress uses different non-glucosydic 
substrates for gluconeogenesis such as glycerol, alanine, pyruvate and lactate. The last two 
mentioned molecules are generated when aerobic glucolysis and Kreb’s cycle is impaired 
(23). In particular, lactate is produced because of inhibition of the pyruvate-dehydrogenase 
enzyme, mainly by IL-1, IL-6 and Tumoral Necrosis Factor-alpha (TNF-α) (33,34). The 
aminoacids alanine and glutamine are substrate for gluconeogenesis of critical illness. They 
are derived from proteolysis of skeletal muscle (33). The alanine is converted to glucose via 
Cori´s cycle (29). Glycerol is a product of lypolisis, and might be elevated because of the 
action of several counter-regulatory hormones (29), glycerol is used as a substrate of 20% of 
hepatic-derived glucose (29).  
The role of the counterregulatory hormones 
Hyperglycemia severity is directly correlated with the intensity of the inflammatory 
response (6). It is well known that inflammation produces an endocrine response that 
releases the so called “stress hormones” that raise glucose plasma levels. A wide variety of 
both hormones and cytokines affect glucose homeostasis by different pathways, including 
the promotion of gluconeogenesis or provoking insulin resistance; when hypoglycemia 
becomes present (less than 70 mg/dl, 3.9 mmol/l) there is a correlation with the initial 
threshold for releasing counterregulatory hormones and cytokines (35,36).  
In healthy people, when gluconeogenesis is augmented, glucagon production is inhibited 
and insulin is released to the circulation; in the post-operated patient, there is an 
inflammatory response in which endogenous –or exogenous- cytokines and cathecolamines 
may interfere with this negative-feedback system and allow a hyperglycemic state by 
augmenting hepatic gluconeogenesis and glycogenolysis (34).  
Although adrenaline, noradrenaline and cortisol are the best-studied hormones in the 
metabolic response to trauma, the most important stress hormone in postsurgical stress is 
the Growth Hormone (37). In other hand, adrenaline and noradrenalin are cathecolamines 
that greatly impair carbohydrates’ metabolism. Adrenaline has shown to increase hepatic 
gluconeogenesis (29, 38), favors glycogenolysis in skeletal muscle and impairs glucose 
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uptake in peripheral tissues, and via the -3 adrenergic receptor, elevates free fatty acids 
(FFAs) in plasma (39). Likewise, noradrenaline may promote gluconeogenesis because its 
lipolytical effects and the marked glycerol supply to the liver (40). The glucogenolytic state 
mediated by these cathecolamines lasts no more than 36 hours (29). Additionally, cortisol is 
a major insulin counterregulatory hormone, which stimulates hepatic glucose production 
and enhances renal glucose production through glyconeogenesis, favors the presence of 
FFAs in plasma (34,41).  
Growth Hormone is a very well known “diabetogenic” hormone and is the most important 
counterregulatory hormone present in surgical stress. It inhibits the insulin signaling 
cascade and it has been demonstrated in experimental animals to reduce the number of 
insulin receptors, as well as it reduces the phosphorylation on tyrosine residues triggered by 
insulin (42). Growth hormone also raises FFAs into plasma, and greatly affects the GLUT-1 
and GLUT-4 activity (43). The Insulin-like Growth Factor (IGF-1 and -2) characterizes 
hepatic resistance to insulin’s action, it has been proved that it keeps a direct association 
with mortality (44). There is not a clear relationship between every individual hormonal 
response that may result in a common phenomenon: hyperglycemia. More research is 
needed for augmenting our knowledge about hormonal regulation of this phenomenon, and 
also for understanding the role and importance of each one of these endocrine signals. 
Figure 2 shows how stress hormones might disrupt glucose metabolism by causing 
resistance to insulin’s action and starting the usage of non-glucosydic substrates that 
contribute to raise glycemia. 
 
 
 
 
Fig. 2. The release of stress hormones produces gluconeogenesis and peripheral resistance to 
insulin. Stress hormones might disrupt glucose metabolism by causing resistance to 
insulin’s action in the GLUT-4 transporter and originates the usage of non-glucosydic 
substrates, that contribute to raise glycemia. GH: Growth Hormone. NGS: non glucosydic 
substrates. 
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The role of the inflammatory response 
Surgical stress establishes an acute inflammatory response that promotes the release of 
different cytokines –specifically TNF-α, IL-1, IL6- from mononuclear cells, this contributes to 
insulin resistance (29) and raising glucose levels in blood; at the same time, induces the 
production of diverse pro-inflammatory and mitogen cytokines like the nuclear factor 
kappa-B (NF-kB), the Early Growth Response-1 gene, the Plasminogen Activator Inhibitor-1 
(PAI-1), Intracellular Adhesion Molecule-1 (iCAM-1), Monocyte Chemotactic Protein-1 
(MCP-1) and matrix metalloproteinases-1, -2 and -9. 
The mechanism whereby TNF- mediates stress hyperglycemia has been well studied. This 
cytokine causes insulin resistance in both liver and skeletal muscle (6) most likely through 
the modification of signaling properties of insulin receptor substrates. In particular, 
endotoxin derived from cell wall of Gram-negative bacterial is also a potent stimulant of 
secondary production of TNF- and various proximate interleukins, mainly IL-1 and -6 
which disrupt both the insulin post-receptor signaling and the phosphorylation of molecules 
associated to the tyrosine-kinase receptor that lastly affects GLUT’s activity, and glucose 
uptake (32, 45). 
The Nuclear Factor kappa-B (NF-kB) is a pleiotropic transcription factor that is present in 
almost all cell types and is involved in many biological processes such as inflammation, 
immunity, cell differentiation, growth and apoptosis, and carcinogenesis. The early growth 
respone-1 gene is a nuclear protein that functions as a transcriptional regulator that favors 
cell differentiation and mitogenesis. The intracellular Adhesion Molecule-1 (iCAM-1) favors 
leucocyte adhesion, and metalloproteinases help in extracellular matrix remodeling (46-48). 
Hyperglycemia affects immune cellular responsiveness by reducing neutrophyle activation, 
chemotactism, fagocytosis, and diminishing bactericidal activity of the reactive oxygen 
species (ROS). Humoral-cell response is affected by immunoglobulin glycosylation and 
altered synthesis of IL-6 and TNF- (6,9). As mentioned, hyperglycemia has been associated 
to an altered immune response, an enhanced proinflammatory response, endothelial 
dysfunction, a hypercogulability state as well as neural damage with an augmented 
oxidative stress and secondary release of ROS from leucocytes (8,49).  
All conditions above mentioned make up a not favorable setting for the surgical patient and 
represent a challenge to reach out a condition of stable normoglycemia. Figure 3 shows the 
relationship in between the abnormal glucose usage and how does physiological stress 
modifies the carbohydrate metabolism, leading to a deleterious non-homeostatic condition. 
3. The stress hyperglycemia and adverse outcomes in surgical patients 
The hyperglycemic response to acute stress induced by surgery was initially considered a 
beneficial-adaptive response, being the raised blood glucose a ready “source of fuel” for 
several tissues including the neural and cardiac-muscle cells. However, retrospective studies 
in patients undergoing cardiac surgery have suggested that perioperative hyperglycemia 
was associated with an increased risk of post-operative infections and an increased 
mortality (50-52). Furthermore, these studies suggested that control of blood glucose 
reduced these complications. The severity of hyperglycemia depends on many factors as 
showed in Table 1. There are different mechanisms in which a variety of risk factors affect 
the glucose metabolism and insulin responsiveness (53). Specifically, on surgery- 
invasiveness: the more invasive the surgery, the more intense the hyperglycemia (11, 54). 
Stress hyperglycemia has many deleterious effects, including vasodilatation, impaired 
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Fig. 3. The relationship between the abnormal glucose usage and physiological stress is 
exposed. Stress modifies the carbohydrate metabolism, the augmented glucose production 
and a diminished glucose uptake raises blood glucose levels, as well as the glucose 
intracellular metabolism is deviated. 
reactive endothelial nitric oxide generation, decreased complement function, increased 
expression of leukocyte and endothelial adhesion molecules, increased cytokine levels, and 
impaired neutrophyle chemotaxis and phagocytosis, leading to increased inflammatory 
state and infection-vulnerability, and multiorgan system dysfunction (55). Others effects of 
excessive glucose levels include the impairment in hepatic functions, abolishment of 
ischemic preconditioning, and protein glycosylation (56). 
Cardiac Surgery has been traditionally considered a highly-invasive procedure (57, 58) and 
taking in account that the hyperglycemic response is increased by anesthetics and the 
preoperative emotional stress (59), this major surgery, induces the release of several counter-
regulatory hormones and deeply modifies the metabolism of carbohydrates, causing 
increased hepatic gluconeogenesis, insulin resistance in various peripheral tissues, and the 
relative insulin production deficiency (60,61). This insulin resistance has been related to an 
increased risk of postoperative complications in cardiac surgery, regardless of the patient´s 
diabetic status (62). 
These metabolic and physiological responses to surgical stress often cause maintaining 
euglycemia during a cardiac surgery, to become a very difficult goal. Nevertheless, the 
reports about association of hyperglycemia and adverse outcomes in cardiac surgery make 
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the glycemic control, something indispensable. Cardiac surgery mortality, tightly correlated 
to glucose blood levels, becomes significant lower when glycemia reaches less than 150 
mg/dl (63) and it raises to even 17% with every 1 mmole/l (18 mg/dl) over 6.8 mmole/l 
(110 mg/dl) (61,64). Hyperglycemia during cardiac procedures and pulmonary bypass is 
severe, particularly in diabetic patients - who comprise a significant percentage of the 
patient population that undergo cardiac surgery. As it was commented, this impairment in 
glucose metabolism is related considerably to the metabolic response to surgical trauma, but 
it is associated mostly to specific aspects of cardiopulmonary bypass, such as heparinization, 
hypothermia, and rewarming (65, 66). 
Independently of controversy about the reports on tight control of glycemia during 
perioperative period, is well known than poor perioperative glycemic control is associated 
with an increased morbidity and mortality. 
4. Approaches on glycemic control during the perioperative period in cardiac 
surgery 
In 2001, van den Berghe and coworkers (67) published a “landmark study” named “The 
Leuven Intensive Insulin Therapy Trial”. In this study, they demonstrated that in critically-ill 
patients –the majority of them undergoing cardiac surgery- the Tight Glycemic Control (TGC) 
(blood glucose between 80-110 mg/dl) using intensive insulin therapy (IIT), improved the 
general clinical outcome (significant reduction in mortality; 42%) (67). After this study was 
published, TGC became rapidly adopted as the reference standard of care in surgical ICUs 
throughout the world (63, 68). The publication of new randomized controlled trials has 
diminished the initial enthusiasm on TGC because it has also been linked with increased 
morbidity and mortality. In last decade, there have been reports about the IIT has led to an 
increased iatrogenic rate of hypoglycemia episodes, emerging as an important risk factor for 
mortality exceeding, in some cases, the mortality-risk associated with hyperglycemia. In fact, 
even moderate and short hypoglycemia events in the ICU can produce permanent brain 
damage (69). After van den Berghe’s work, two multicenter-randomized European studies 
were prematurely discontinued due to an alarmingly high rate of hypoglycemia in the TGC 
arm, showing no mortality benefits (70, 71). Two additional single centers, randomized studies 
showed a trend towards a higher mortality in the TGC arm (72, 73). TGC is strongly associated 
with an even sixfold-increase in episodes of severe hypoglycemia (glucose levels < 2.2 
mmole/l, 40 mg/dl) (20) and, as mentioned before, this state can have dramatically adverse 
effects such as coma or even death (74). The recent NICE-SUGAR study showed that an 
intensive glucose control increased mortality among ICU adults, and that an 81-108 mg/dl 
target was too ambitious and potentially dangerous (12). 
On the other hand, glucose variability has emerged as another important factor associated 
with mortality (75). Glucose profiles from patients are characterized by important 
fluctuations, even during continuous intravenous insulin infusion. However, many of the 
reported trials have evaluated the effects of IIT based on the absolute glucose levels, 
although clinical effects of IIT should be interpreted using temporal courses (76, 77). From 
this point of view, we should consider simultaneously the combined and independent 
clinical impact of glycemia’s sudden fluctuations, glycemia temporal trends, and glycemia 
variability during hospitalization. In this way of thought, in a study including over 7,000 
critically ill patients was demonstrated that the standard deviation of glucose concentration 
is a significant independent predictor of ICU and hospital mortality (78). Recently, it has 
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been reported a relationship between ICU mortality and glucose variability in a cohort of 
5,728 patients managed with IIT (79). 
Although there is agreement that both hyperglycemia and hypoglycemia are deleterious, and 
that we should consider the fluctuations in blood glucose levels, there is no a consensus on the 
target glucose values to enhance desirable clinical outcomes. In this regard, relatively recent 
guidelines have been published from different international study-groups, like the American 
College of Physicians (ACP), American Diabetes Association (ADA), American Association of 
Clinical Endocrinologists (AACE) and the European Society of Cardiology (ESC) (80,81). The 
next section is related with recommendations about management of hyperglycemia in both 
patients with and without diabetes undergoing cardiac surgical, and the procedures that 
should be taken into account during the perioperative period, obtained from the Society of 
Thoracic Surgeons (STS) Practice Guideline series (81), which is derived in turns from 
evidence-based recommendations. We consider these guidelines as the most important work 
on the glucose management in cardiac surgery and we mention several paragraphs textually. 
In summary, these useful guidelines offer some central ideas about the management of 
glycemia during cardiac surgery. The first of them is about detrimental effects of 
hyperglycemia in perioperative period, and they highlight that poor perioperative glycemic 
control is associated with increased morbidity and mortality, quoting the guidelines: 
“Collectively, these studies strongly suggest that increased fasting glucose levels during and 
immediately after cardiac surgery, are predictive of increased perioperative morbidity and 
mortality in patients with and without diabetes” (81). In this regard, the following central idea 
is about the beneficial effects of glycemic control on clinical outcomes during cardiac surgery, 
and afterwards, it recommends - after a review of the most important randomized trials - a 
glycemic control <180 mg/dl, mainly in patients with diabetes during cardiac surgery. 
In the following paragraph, guidelines are focused about glycemic control in patients 
without diabetes during cardiac surgery, and they point –after analyzing several 
randomized trials of good quality- that “intraoperative glycemic control using intravenous 
insulin infusions is not necessary in cardiac surgery patients without diabetes, as well as 
glucose values remain < 180 mg/dl. This previous conclusion was obtained from the 
comparison between groups with TGC using IIT and without insulin finding no difference 
in the primary outcome, which consisted of the composite incidence of death, sternal wound 
infections, prolonged ventilation, cardiac arrhythmias, strokes, and renal failure within 30 
days of surgery (82). There was also no difference in ICU or hospital stay between the 
groups. There was a tendency for more deaths (p=0.06) and strokes (p=0.02) in the IIT”. 
In the next section, the guidelines point to management of hyperglycemia using insulin 
protocols in the perioperative period considering that intravenous insulin therapy is the 
preferred method of insulin delivery during this period. It is used an evidence-based 
recommendations, depending on the procedure it is classified as beneficial, useful and 
effective (table 3; ref. 81). The recommendations class I are based on when glycemic control 
is best achieved with continuous insulin infusions rather than intermittent subcutaneous 
insulin injections or intermittent intravenous insulin boluses (level of evidence A). In 
addition, all patients with diabetes undergoing cardiac surgical procedures should receive 
an insulin infusion in the operating room, and for at least 24 hours postoperatively to 
maintain serum glucose levels 180 mg/dl (level of evidence=B; table 3).  
Following the recommendations of the guidelines, the next part refers to the perioperative 
management and assessment for patients with diabetes. The next recommendations are 
classified after an exhaustive analysis of several trials with this kind of patients. Thus, we  
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Action Factor 
Lypolisis 
Adrenaline 
Noradrenaline 
Growth Hormone 
Enhanced Gluconeogenesis 
Glucagon 
Glucocorticoids 
Growth Hormone 
Supression of Insulin Secretion 
Adrenaline 
Glucocorticoids (Cortisol) 
Glucogenolysis 
Adrenaline 
Glucagon 
Peripheral Insulin Resistance 
Tumoral Necrosis Factor alpha 
Adrenaline 
Glucocorticoids (Cortisol) 
Growth Hormone 
Hepatic Insulin Impairment Tumoral Necrosis Factor alpha 
Modified from ref. 29:  McCowen KC, Malhotra A, Bistrian BR. Stress-induced hyperglycemia. Crit Care 
Clin 2001; 17: 107-24. 
Table 2. Major actions of counterregulatory hormones and cytokines in stress hyperglycemia 
 
Class I: Conditions for which there is evidence for and/or general agreement that the 
procedure is beneficial, useful, and effective. 
Class II: Conditions for which there is conflicting evidence and/or a divergence of opinion 
about the usefulness/efficacy of a procedure or treatment 
Class IIA: Weight of evidence/opinion is in favor of usefulness/efficacy 
Class IIB: Usefulness/efficacy is less well-established by evidence/opinion 
Class III: Conditions for which there is evidence or general agreement that the 
procedure/treatment is not useful/effective, or both, and in some cases may be harmful 
Level of Evidence – A: Data derived from multiple randomized clinical trials 
Level of Evidence – B: Data derived from a single randomized trial or nonrandomized 
studies 
Level of Evidence – C: Only consensus opinion of experts, case studies, or standard- of-
care 
Modified from ref. 81: Lazar. Ann Thorac Surg 2009; 87: 663-669. 
Table 3. Classification system used for evidence based recommendations from society of 
thoracic surgeons practice guidelines 
have summarized the experience of these trials. Class I: a) “patients taking insulin should 
hold their nutritional insulin after dinner the evening prior to surgery (level of evidence=B). 
b) Scheduled insulin therapy, using a combination of long-acting and short-acting 
subcutaneous insulin, or an insulin infusion protocol, should be initiated to achieve 
glycemic control for in-hospital patients awaiting surgery (level of evidence=C; table 3). c) 
All oral hypoglycemic agents and noninsulin diabetes medications should be held for 24 
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hours prior to surgery (level of evidence=C). d) The hemoglobin A1c (HbA1c) level should 
be obtained prior to surgery in patients with diabetes or those patients at risk for 
postoperative hyperglycemia to characterize the level of preoperative glycemic control” 
(level of evidence=C; table 3). Class IIA. Prior to surgery, it is reasonable to maintain blood 
glucose concentration  180 mg/dl (level of evidence=C; table 3). Efforts should be made to 
optimize glucose control prior to surgery, because poor preoperative glycemic control has 
been associated with increased mortality, including a higher incidence of deep sternal 
wound infections and prolonged postoperative length of stay. In general, all oral diabetes 
medications should be withheld within 24 hours prior to surgery, especially sulfonylureas 
(eg, glipizide) and glinides (eg, nateglinide or repaglinide). These drugs can induce 
hypoglycemia in the absence of food. Patients who are taking insulin and who are admitted 
on the day of surgery should be instructed to continue their basal insulin dose (eg, glargina, 
determir or NPH) and hold their nutritional insulin (eg, lispro, aspart, glulisine, or regular) 
unless instructed otherwise by their primary physician. The NPH insulin may be reduced by 
one half or one third of the dose prior to surgery to avoid hypoglycemia. 
“To achieve rapid control in hospitalized patient with hyperglycemia (glucose  180 mg/dl 
for more than 12 hours before surgery), insulin therapy -either with intravenous variable-
rate continuous infusion or subcutaneous basal plus rapid-acting insulin- should be used 
depending on the availability of either therapy. For the hyperglycemic patient in the 
preoperative area, on the day of surgery, IV insulin therapy is an effective way to achieve 
immediate control. Patients with a known history of diabetes (either type 1 or type 2) can be 
started immediately on IV therapy in the preoperative area. All preoperative medications 
should be reviewed to determine the potential for insulin resistance. These include steroids, 
protease inhibitors, and anti-psychotic drugs. Finally, patients with renal insufficiency 
should be identified, because insulin clearance is impaired and the risk for hypoglycemia is 
increased”. 
Next section is the “intraoperative control recommendations”. Above recommendations are 
classified upon the level of evidence and quality of trials. Class I.  a) Glucose levels  180 
mg/dl that occur in patients without diabetes only during cardiopulmonary bypass may be 
treated initially with a single or intermittent dose of IV insulin as long as levels remain  180 
mg/dl. However, in those patients with persistently elevated serum glucose ( 180 mg/dl) 
after cardiopulmonary bypass, a continuous insulin drip should be instituted, and an 
endocrinology consult should be obtained (level of evidence = B; table 3). b) If an 
intravenous insulin infusion is initiated in the preoperative period, it should be continued 
throughout the intraoperative and early postoperative period according to institutional 
protocols to maintain serum glucose  180 mg/dl (level of evidence = C; table 3).  
Concerning glycemic control in the ICU, guidelines recommend the following procedures: 
Recommendation Class I. a) Patients with and without diabetes with persistently elevated 
serum glucose ( 180 mg/dl) should receive IV insulin infusion to maintain serum glucose  
180 mg/dl for the duration of their ICU care (level of evidence = A; table 3). b) All patients 
who require  3 days in the ICU because of ventilatory dependency or requiring the need for 
inotropes, intra-aortic balloon pump, or left ventricular assist device support, anti-
arrhythmics, dialysis, or continuous veno-venous hemofiltration should have a continuous 
insulin infusion to keep blood glucose   150 mg/dl, regardless of diabetic status (level of 
evidence =B; table 3). b) Before intravenous insulin infusions are discontinued, patients 
should be transitioned to a subcutaneous insulin schedule using institutional protocols 
(level of evidence=B; table 3). 
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Finally, the Glycemic control in the stepdown units and on the floor recommendations is the 
last part of the guidelines. Class I. a) A target blood glucose level  180 mg/dl should be 
achieved in the peak postprandial state (level of evidence = B; table 3). b) A target blood 
glucose level  110 mg/dl should be achieved in the fasting and pre-meal states after 
transfer to the floor (level of evidence = C; table 3). c) Oral hypoglycemic medications 
should be re-started in patients who have achieved target blood glucose levels if there are no 
contraindications. Insulin dosages should be reduced accordingly (level of evidence = C; 
table 3). d) According to the AACE, a reasonable goal for a noncritically ill patient on a 
regular hospital ward is  110 mg/dl and 180 mg/dl postprandial or randomly (83). The 
best method to realize this control is with scheduled subcutaneous basal and, or bolus 
insulin therapy, such as glargine or determir (basal) and lispro, aspart, or glulisine (bolus). 
Patients with type 2 diabetes who have used oral diabetes medications preoperatively can 
be restarted on those medications once they have reached their targeted glucose goals and 
are eating a regular diet. Metformin should not be restarted until stable renal function has 
been documented. In relation to preparation for hospital discharge, the guidelines 
recommend that prior to discharge, all patients with diabetes and those who have started a 
new glycemic control regimen, should receive in-patient education regarding glucose 
monitoring, medication administration (including subcutaneous insulin injection if 
necessary), nutrition, and lifestyle modification (level of evidence = C, table 3). Upon 
discharge, changes in therapy for glycemic control should be communicated to primary care 
physicians, and follow up appointments should be arranged with an endocrinologist when 
appropriate (level of evidence = C, table 3). All patients with hyperglycemia after cardiac 
surgery should be assessed by an inpatient diabetes team to decide on a glycemic control 
program after discharge. 
The conditions that are important to consider are, in summary: avoidance of deep 
hypothermia, excessive blood losses, a prolonged preoperative fasting period and 
prolonged immobilization, because all these conditions augment perioperative insulin 
resistance. In addition, considering that most anesthetic agents cause hyperglycemia, the 
choice of anesthetic agent will be influenced by the severity of systemic diseases, such as 
coronary artery disease, nephropathy (with the concomitant risk of hyper/hypokalemia and 
other hidroelectrolytic disorders), and hypertension, and the choice of neuromuscular 
blocking agent will be affected by renal function. 
5. Conclusion 
Although reports differ, and not enough data are available to allow specifying optimal 
treatment goals or the best approach to perioperative management of glycemia, it is clear 
that surgical outcomes are improved in patients who are maintained in good metabolic 
control. Physicians must be cognizant of patients´ preoperative control, in diabetic patients,  
their relative need for insulin, and any factors that may be likely to increase insulin 
requirements. The guidelines presented here represent just an approximate approach based 
in evidence with different qualities. So, the administration of adequate glucose in 
conjunction with the judicious use of insulin will prevent hypoglycemia. However, diabetic 
ketoacidosis or hyperosmolar states, which may result from inadequate dosing of insulin, 
are not so easily managed. The key to success of any perioperative management plan is 
frequent monitoring of glucose, electrolyte, and fluid levels, and acid-base status. 
Prevention of surgical complications as a result of hyperglycemia is possible with 
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meticulous perioperative glucose management. Finally, we need further research to be done 
to provide definitive answers on the benefits of tight glycemic control for cardiac surgery 
patients. 
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